DISCLAIMER: This site is for informational purposes only. While we make every effort to keep it up to date, there is no guarantee that information is complete, accurate, comprehensive, or the same for all KP regions. The information on this site should not be interpreted or used as a substitute for professional medical care. Please consult your care provider for any personal health questions or before participating in clinical trials.

Active, currently enrolling

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older (BEETHOVEN)

NCT No.: NCT07282665

Study Type: INTERVENTIONAL

Phase: Phase III

Region: California - Northern

Acronym: BEETHOVEN

Official Title

A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older (BEETHOVEN)

Purpose

The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. difficile vaccine or placebo (saline). A placebo does not contain any active ingredients. The vaccines will be given as a shot into the upper arm muscle. This study looks at the number of diarrhea (loose stools) events related to a C. difficile infection, so the length of the study can change. If these events happen quickly, the study may finish sooner; if they happen slowly, it could take longer. Sometimes, the study might stop early if the vaccine clearly works or clearly doesn't. Participants will stay in the study until enough events have occurred to answer the main question. On average, each person is expected to take part for up to about three and a half years. During this time, participants will have 3 planned clinical visits and 3 planned phone visits. After these visits, more scheduled clinic visits will happen every year until the end of study. Besides the scheduled study visits, if at any time during the study a participant has 3 or more loose stools in 24 hours, they will be asked to save the next one (the fourth or later) and contact the study site. The study site will check to see if it could be a C. difficile infection. This check may happen at the clinic or through a phone or video call.

Detailed Description

Sex

Male & Female

Age Limit

Eligibility Criteria

Inclusion Criteria

• People with recent or future planned contact with healthcare systems or who have recently received antibiotics.

Exclusion Criteria

• Anyone who has had CDI before.
• Anyone who has had surgery to remove part of their small or large intestine.
• Anyone who often has diarrhea (meaning three or more loose stools in a day, more than once a month).
• Anyone who has already received a vaccine or special antibody treatment for C. difficile.
• Anyone who has had a serious allergic reaction to a vaccine or to any part of the study vaccines.
• Anyone who might not respond well to the vaccine because their immune system is weak (either from a disease or from treatment).
• Anyone with cancer that has spread, kidney failure, or another serious health problem.

Keywords and/or Specific Medical Conditions

  • adults 65 years and older
  • C. diff
  • C. difficile
  • CDI
  • Clostridioides difficile vaccine
  • Geriatric Medicine
  • healthcare-associated infection
  • infectious diarrhea
  • Clostridioides difficile infection
  • Preventative Medicine

Sponsors

  • Pfizer

Principal Investigator

Nicola Klein , MD, PhD 

Contact Information

 - KPNC Vaccine Study Center
- 1-833-311-0325
- vaccinestudycenter@kp.org
- All Kaiser Permanente Northern California Medical Centers

Find a study